A DEFENSIBLE METHOD
Evidence and market readiness methodology
Scores make editorial judgement visible. They do not convert uncertainty into certainty or replace regulatory decisions.
Evidence grades
| Grade | Minimum interpretation |
|---|---|
| A | Authorised indication or robust pivotal human evidence directly relevant to the stated proposition. |
| B | Meaningful controlled human evidence, but not an authorised indication or not yet mature enough for Grade A. |
| C | Limited human, observational, translational or predominantly preclinical evidence. |
| D | Market, clinic or mechanistic signal without adequate controlled combination or indication level evidence. |
Grades are proposition specific and are not treatment recommendations.
UK readiness score
The current 0 to 10 score combines regulatory maturity, relevant human evidence, UK authorisation, NICE activity, NHS pathway visibility and practical service preparedness.
- 0 to 2: surveillance only
- 3 to 4: early development or material international signal
- 5 to 6: late stage or filing territory
- 7 to 8: authorised or a clear UK access pathway
- 9 to 10: established UK clinical and implementation maturity
The score does not by itself establish access in Wales, Scotland or Northern Ireland. The Republic of Ireland will use a separate readiness assessment once HPRA, NCPE and HSE fields have been verified.
National access matrix
Each market is checked through three separate layers: authorisation for the exact product and indication, assessment by the relevant national body, and evidence of a practical funded or private access route. An absent or pending national field is not inferred from another country.
Editorial independence and conflicts
Payment, sponsorship or customer status cannot alter evidence grades, regulatory descriptions or readiness scoring. Financial, advisory or data supply relationships relevant to a record must be disclosed. A conflicted contributor cannot provide the final editorial verification for that record.
Professional boundary
Peptide Readiness provides evidence, regulatory, exposure and readiness intelligence. It does not diagnose, prescribe, recommend individual treatment, provide dosing or reconstitution instructions, validate unlicensed products or refer visitors to unlicensed sellers.